Orphazyme delays annual report again after striking deal with Kempharm
.jpg)
Orphazyme, a listed company in Denmark that has been restructuring since March, has postponed its annual report for 2021 yet again, a company press release states.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme sells entire business to US biotech company
For subscribers
Orphazyme didn't know buyer before negotiations began
For subscribers
Orphazyme reveals new release date for 2021 report
For subscribers